BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32250304)

  • 1. Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.
    Robinson RL; Rentz DM; Andrews JS; Zagar A; Kim Y; Bruemmer V; Schwartz RL; Ye W; Fillit HM
    J Alzheimers Dis; 2020; 75(2):437-450. PubMed ID: 32250304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observation of Patient and Caregiver Burden Associated with Early Alzheimer's Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study1.
    Robinson RL; Rentz DM; Bruemmer V; Scott Andrews J; Zagar A; Kim Y; Schwartz RL; Ye W; Fillit HM
    J Alzheimers Dis; 2019; 72(1):279-292. PubMed ID: 31561360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
    Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
    J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease.
    Reed C; Belger M; Vellas B; Andrews JS; Argimon JM; Bruno G; Dodel R; Jones RW; Wimo A; Haro JM
    Int Psychogeriatr; 2016 Feb; 28(2):247-59. PubMed ID: 26307191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
    Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
    Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer's Disease Continuum Using Patient-Caregiver Dyad Surveys.
    Tahami Monfared AA; Khachatryan A; Hummel N; Kopiec A; Martinez M; Zhang R; Zhang Q
    J Alzheimers Dis; 2024; 99(1):191-206. PubMed ID: 38640156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Economic Assessment in Early-Stage Dementia by Severity and Amyloid-β Status: A 5-Year Retrospective Claims Study of GERAS-US Patients.
    Chandler J; Kubisiak J
    J Alzheimers Dis; 2023; 91(2):753-765. PubMed ID: 36502319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.
    Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Treuer T; Sato M; Kahle-Wrobleski K; Meguro K; Yamada M; Mimura M; Arai H
    J Alzheimers Dis; 2020; 74(1):127-138. PubMed ID: 31985460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
    Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
    Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
    Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
    Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours.
    Haro JM; Kahle-Wrobleski K; Bruno G; Belger M; Dell'Agnello G; Dodel R; Jones RW; Reed CC; Vellas B; Wimo A; Argimon JM
    J Nutr Health Aging; 2014 Jul; 18(7):677-84. PubMed ID: 25226106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
    Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
    J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer's disease.
    Lebrec J; Ascher-Svanum H; Chen YF; Reed C; Kahle-Wrobleski K; Hake AM; Raskin J; Naderali E; Schuster D; Heine RJ; Kendall DM
    BMC Geriatr; 2016 May; 16():93. PubMed ID: 27142529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.
    Reed C; Happich M; Argimon JM; Haro JM; Wimo A; Bruno G; Dodel R; Jones RW; Vellas B; Belger M
    J Alzheimers Dis; 2017; 57(3):797-812. PubMed ID: 28304285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study.
    Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Matsumura T; Meguro K; Yamada M; Mimura M; Arai H; Treuer T
    Curr Med Res Opin; 2021 Aug; 37(8):1331-1339. PubMed ID: 33904362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.
    Dodel R; Belger M; Reed C; Wimo A; Jones RW; Happich M; Argimon JM; Bruno G; Vellas B; Haro JM
    Alzheimers Dement; 2015 Aug; 11(8):933-45. PubMed ID: 25846298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study.
    Chandler JM; Ye W; Mi X; Doty EG; Johnston JA
    J Alzheimers Dis; 2024 Jun; ():. PubMed ID: 38875031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.
    Belger M; Haro JM; Reed C; Happich M; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
    Eur J Health Econ; 2019 Apr; 20(3):343-355. PubMed ID: 30178148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.